Inhibition of phosphatidylinositol 3-kinase catalytic subunit alpha by miR-203a-3p reduces hypertrophic scar formation via phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway

Abstract

Background: Hypertrophic scar (HS) is a common fibroproliferative skin disease that currently has no truly effective therapy. Given the importance of phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) in hypertrophic scar formation, the development of therapeutic strategies for endogenous inhibitors against PIK3CA is of great interest. Here, we explored the molecular mechanisms underlying the protective effects of miR-203a-3p (PIK3CA inhibitor) against excessive scar. Methods: Bioinformatic analysis, immunohistochemistry, immunofluorescence, miRNA screening and fluorescence in situ hybridization assays were used to identify the possible pathways and target molecules mediating HS formation. A series of in vitro and in vivo experiments were used to clarify the role of PIK3CA and miR-203a-3p in HS. Mechanistically, transcriptomic sequencing, immunoblotting, dual-luciferase assay and rescue experiments were executed. Results: Herein, we found that PIK3CA and the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway were upregulated in scar tissues and positively correlated with fibrosis. We then identified miR-203a-3p as the most suitable endogenous inhibitor of PIK3CA. miR-203a-3p suppressed the proliferation, migration, collagen synthesis and contractility as well as the transdifferentiation of fibroblasts into myofibroblasts in vitro, and improved the morphology and histology of scars in vivo. Mechanistically, miR-203a-3p attenuated fibrosis by inactivating the PI3K/AKT/mTOR pathway by directly targeting PIK3CA. Conclusions: PIK3CA and the PI3K/AKT/mTOR pathway are actively involved in scar fibrosis and miR-203a-3p might serve as a potential strategy for hypertrophic scar therapy through targeting PIK3CA and inactivating the PI3K/AKT/mTOR pathway.

Keywords

Fibrosis / Hypertrophic scar / miRNA / Phosphatidylinositol 3-kinase catalytic subunit alpha / Transdifferentiation / miR-203a-3p / Phosphatidylinositol 3-kinase / AKT / mTOR

References

[1] Finnerty CC, Jeschke MG, Branski LK, Barret JP, Dziewulski P, Herndon DN. Hypertrophic scarring: the greatest unmet challenge after burn injury. Lancet. 2016; 388: 1427-36.

[2] Zhou Q, Gong J, Bi J, Yang X, Zhang L, Lu C, et al. KGF-2 regulates STAP-2-mediated signal transducer and activator of transcription 3 Signaling and reduces skin scar formation. J Invest Dermatol. 2022; 142: 2003-13.e5.

[3] He J, Fang B, Shan S, Xie Y, Wang C, Zhang Y, et al. Mechanical stretch promotes hypertrophic scar formation through mechanically activated cation channel Piezo1. Cell Death Dis. 2021; 12: 226.

[4] Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020; 31: 377-86.

[5] Buchanan CM, Dickson JM, Lee WJ, Guthridge MA, Kendall JD, Shepherd PR. Oncogenic mutations of p110 α isoform of PI 3-kinase upregulate its protein kinase activity. PLoS One. 2013; 8: e71337.

[6] Maheshwari S, Miller MS, O’Meally R, Cole RN, Amzel LM, Gabelli SB. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition. J Biol Chem. 2017; 292: 13541-50.

[7] Jiang W, He T, Liu S, Zheng Y, Xiang L, Pei X, et al. The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer. J Hematol Oncol. 2018; 11: 139.

[8] Liu W, Zheng L, Zhang R, Hou P, Wang J, Wu L, et al. Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma. Mol Cancer. 2022; 21: 72.

[9] Wegner KA, Mueller BR, Unterberger CJ, Avila EJ, Ruetten H, Turco AE, et al. Prostate epithelial-specific expression of activated PI3K drives stromal collagen production and accumulation. J Pathol. 2020; 250: 231-42.

[10] Yang X, Li X, Lin Q, Xu Q. Up-regulation of microRNA-203 inhibits myocardial fibrosis and oxidative stress in mice with diabetic cardiomyopathy through the inhibition of PI3K/Akt signaling pathway via PIK3CA. Gene. 2019; 715: 143995.

[11] Steiner JE, Cottrell CE, Streicher JL, Jensen JN, King DM, Burrows PE, et al. Scarring in patients with PIK3CA-related overgrowth syndromes. JAMA Dermatol. 2018; 154: 452-5.

[12] Li Y, Zhang J, Shi J, Liu K, Wang X, Jia Y, et al. Exosomes derived from human adipose mesenchymal stem cells attenuate hypertrophic scar fibrosis by miR-192-5p/IL-17RA/Smad axis. Stem Cell Res Ther. 2021; 12: 221.

[13] Jin ZQ. MicroRNA targets and biomarker validation for diabetes-associated cardiac fibrosis. Pharmacol Res. 2021; 174: 105941.

[14] Li J, Li P, Zhang G, Qin P, Zhang D, Zhao W. CircRNA TADA2A relieves idiopathic pulmonary fibrosis by inhibiting proliferation and activation of fibroblasts. Cell Death Dis. 2020; 11: 553.

[15] Liu SY, Wu JJ, Chen ZH, Zou ML, Teng YY, Zhang KW, et al. The m6A RNA modification modulates gene expression and fibrosis-related pathways in hypertrophic scar. Front Cell Dev Biol. 2021; 9: 748703.

[16] Kisiel MA, Klar AS. Isolation and culture of human dermal fibroblasts. Methods Mol Biol. 2019; 1993: 71-8.

[17] Zhou S, Wang W, Zhou S, Zhang G, He J, Li Q. A novel model for cutaneous wound healing and scarring in the rat. Plast Reconstr Surg. 2019; 143: 468-77.

[18] Soulard A, Hall MN. Hall MN. SnapShot: mTOR signaling. Cell. 2007; 129: 434-434.e2.

[19] Fritsch R, Downward J. SnapShot: class I PI3K isoform signaling. Cell. 2013; 154: 940-40. e1.

[20] Cai Y, Xu G, Wu F, Michelini F, Chan C, Qu X, et al. Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3K α inhibitors. Cancer Res. 2021; 81: 2470-80.

[21] Arafeh R, Samuels Y. PIK3CA in cancer: the past 30 years. Semin Cancer Biol. 2019; 59: 36-49.

[22] Leng J, Li H, Niu Y, Chen K, Yuan X, Chen H, et al. Low-dose mono(2-ethylhexyl) phthalate promotes ovarian cancer development through PPAR α-dependent PI3K/Akt/NF-κB pathway. Sci Total Environ. 2021; 790: 147990.

[23] Ashcroft GS, Horan MA, Ferguson MW. Aging is associated with reduced deposition of specific extracellular matrix components, an upregulation of angiogenesis, and an altered inflammatory response in a murine incisional wound healing model. J Invest Dermatol. 1997; 108: 430-7.

[24] Gao Y, Zhou J, Xie Z, Wang J, Ho CK, Zhang Y, et al. Mechanical strain promotes skin fibrosis through LRG-1 induction mediated by ELK1 and ERK signalling. Commun Biol. 2019; 2: 359.

[25] Wen D, Gao Y, Ho C, Yu L, Zhang Y, Lyu G, et al. Focusing on Mechanoregulation Axis in fibrosis: sensing, transduction and effecting. Front Mol Biosci. 2022; 9: 804680.

[26] Shi LL, Zhang RF, Xiao H. Roles of interleukin-6/signal transduction and activator of transcription 3 pathway and β-catenin in mechanical stress-induced hypertrophic scar formation in mice. Zhonghua Shao Shang Za Zhi. 2021; 37: 647-53.

[27] Wang X, Zhang Y, Jiang BH, Zhang Q, Zhou RP, Zhang L, et al. Study on the role of Hsa-miR-31-5p in hypertrophic scar formation and the mechanism. Exp Cell Res. 2017; 361: 201-9.

[28] Zhou X, Xie Y, Xiao H, Deng X, Wang Y, Jiang L, et al. MicroRNA-519d inhibits proliferation and induces apoptosis of human hypertrophic scar fibroblasts through targeting Sirtuin 7. Biomed Pharmacother. 2018; 100: 184-90.

[29] Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16: 203-22.

[30] Guo BY, Lin F, Bai ZM, Tao K, Wang HY. Expression of microRNA-296 in rabbit hypertrophic scars and its role to human fibroblasts. Zhonghua Shao Shang Za Zhi. 2021; 37: 725-30.

[31] Li T, Xing Y, Zhang G, Wang Y, Wei Y, Cui L, et al. Circular RNA Plasmacytoma variant translocation 1 (CircPVT1) knockdown ameliorates hypoxia-induced bladder fibrosis by regulating the miR-203/suppressor of cytokine Signaling 3 (SOCS3) signaling axis. Bioengineered. 2022; 13: 1288-303.

[32] Pakshir P, Hinz B. The big five in fibrosis: macrophages, myofibroblasts, matrix, mechanics, and miscommunication. Matrix Biol. 2018; 68-69: 81-93.

[33] Shi K, Qiu X, Zheng W, Yan D, Peng W. MiR-203 regulates keloid fibroblast proliferation, invasion, and extracellular matrix expression by targeting EGR1 and FGF2. Biomed Pharmacother. 2018; 108: 1282-8.

[34] Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008; 453: 314-21.

[35] Chi Y, Jin Q, Liu X, Xu L, He X, Shen Y, et al. miR-203 inhibits cell proliferation, invasion, and migration of non-small-cell lung cancer by downregulating RGS17. Cancer Sci. 2017; 108: 2366-72.

[36] Wang B, Li X, Zhao G, Yan H, Dong P, Watari H, et al. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGF β pathway. J Exp Clin Cancer Res. 2018; 37: 235.

[37] Shirakami E, Yamakawa S, Hayashida K. Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence. Burns Trauma. 2020; 8: tkz003.

[38] Le LT, Cazares O, Mouw JK, Chatterjee S, Macias H, Moran A, et al. Loss of miR-203 regulates cell shape and matrix adhesion through ROBO1/Rac/FAK in response to stiffness. J Cell Biol. 2016; 212: 707-19.

[39] Miroshnikova YA, Mouw JK, Barnes JM, Pickup MW, Lakins JN, Kim Y, et al. Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression. Nat Cell Biol. 2016; 18: 1336-45.

[40] Hinz B.Formation and function of the myofibroblast during tissue repair. J Invest Dermatol. 2007; 127: 526-37.

[41] Ke XF, Fang J, Wu XN, Yu CH. MicroRNA-203 accelerates apoptosis in LPS-stimulated alveolar epithelial cells by targeting PIK3CA. Biochem Biophys Res Commun. 2014; 450: 1297-303.

[42] Hu X, Xu Q, Wan H, Hu Y, Xing S, Yang H, et al. PI3K-Akt-mTOR/PFKFB3 pathway mediated lung fibroblast aerobic glycolysis and collagen synthesis in lipopolysaccharide-induced pulmonary fibrosis. Lab Investig. 2020; 100: 801-11.

[43] Yang J, Savvatis K, Kang JS, Fan P, Zhong H, Schwartz K, et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun. 2016; 7: 13710.

[44] Wang Q, Wang P, Qin Z, Yang X, Pan B, Nie F, et al. Altered glucose metabolism and cell function in keloid fibroblasts under hypoxia. Redox Biol. 2021; 38: 101815.

[45] Wu X, Luo Y, Wang S, Li Y, Bao M, Shang Y, et al. AKAP12 ameliorates liver injury via targeting PI3K/AKT/PCSK6 pathway. Redox Biol. 2022; 53: 102328.

[46] Bai XZ, Liu JQ, Yang LL, Fan L, He T, Su LL, et al. Identification of sirtuin 1 as a promising therapeutic target for hypertrophic scars. Br J Pharmacol. 2016; 173: 1589-601.

[47] Ehrlich HP, Desmoulière A, Diegelmann RF, Cohen IK, Compton CC, Garner WL, et al. Morphological and immunochemical differences between keloid and hypertrophic scar. Am J Pathol. 1994; 145: 105-13.

[48] Meng X, Yu Z, Xu W, Chai J, Fang S, Min P, et al. Control of fibrosis and hypertrophic scar formation via glycolysis regulation with IR780. Burns. Trauma. 2022; 10: tkac015.

[49] Wang M, Qian L, Li J, Ming H, Fang L, Li Y, et al. GHSR deficiency exacerbates cardiac fibrosis: role in macrophage inflammasome activation and myofibroblast differentiation. Cardiovasc Res. 2020; 116: 2091-102.